Despite a Transfusion Medicine Code of Ethics and an instructive history, (ranging from large-scale tainted blood tragedies to case-inspired laws), new disputes in hemotherapy and cell therapy have arisen to test our frameworks while disrupting consensus. 21st century challenges call for 21st century competencies in critical thinking, communication, collaboration, and creativity.
This interactive session will update the audience on emerging principles, landmark events, and controversies in cellular engineering and transfusion medicine.
Cases for polling and discussion will span CRISPR babies; blood doping for clinical trial eligibility; transfusion support in potentially inappropriate situations (massive blood use in suspected brain death, chronic self-inflicted blood loss in unrestrained psychiatric patients, home transfusions performed by next-of-kin, intensive apheresis for abortifacient isoimmunization), blood management gaps (non-disclosure of donation-related iron deficiency risks, unmitigated intergenerational effects of iron deficiency, resource allocations in hemotherapy-prohibited cases), and resource abuses (unauthorized storages in preservation facilities).
List the evolving codes and source-authorities on best ethical practices in advanced transfusion and cellular therapy
Apply foundational principles to, and identify the available resources (eg. relevant arbitrators) for, a variety of novel scenarios in cell therapy labs and hospital transfusion services
Predict context-specific outcomes based on acting system values and gaps, and the potential reach and risks of actions (eg. resource equity, off-target or prolonged/inter-generational effects)
Please note: Christine Cserti-Gazdewich did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.
Transfusion Medicine Specialist and Hematologist,
Sunnybrook Health Sciences Centre